Sandalwood giant can smell big dollars in warts more

ViroXis Corporation Announces expanded board of directors and advisors more

ITClamp Hemorrhage Control System from Innovative Trauma Care more

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. more

Innovative Trauma Care (ITC), an early-stage medical device firm focused on developing point of injury solutions for trauma, first responder and military medicine applications, has received regulatory approval from Health Canada for commercial sale of its first product, the ITClamp™ Hemorrhage Control System in Canada. The product will be available in the fourth quarter of 2012 for Canadian medical professionals.

The ITClamp was designed to address massive hemorrhage – a leading cause of death in traumatic injury – by controlling critical bleeding in as little as five seconds. The clamping device works by sealing the skin closed to create a temporary pool of blood under pressure, which forms a stable clot until the wound can be surgically repaired.

Health Canada is the Federal department in Canada that reviews medical devices to assess their safety and effectiveness before being authorized for sale in Canada.ITC expects regulatory approval from the European Union in late 2012 and US clearance from the FDA in 2013.

Innovative Trauma Care’s CEO and founder, Dr. Dennis Filips, said, “As a company that is rooted in Canada, we are proud that our home country is the first to recognize the benefits that the ITClamp can provide in saving patients’ lives.”

Incorporated in 2010 and based in Edmonton, Canada with a US headquarters in San Antonio, Texas, Innovative Trauma Care is addressing unmet needs in the field of emergency medicine by developing, manufacturing, and commercializing point of injury solutions to treat common causes of preventable death in traumatic. back

BiO2 Medical, Inc and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding more

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication more

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

BiO2 Medical Announces First in Man Clinical Study more

BiO2 Medical Secures Series B Round Funding more

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia more

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more